Schedule II & RFK ·
The phrase 'coming off Schedule II' appears frequently in 2026 public discussion about peptides but requires careful unpacking. Most peptides of current research interest — including BPC-157, TB-500, CJC-1295, Ipamorelin, and the GLP-1 agonists — are not federally on Schedule II in the first place. The narrative instead generally refers to a combination of (a) state-level scheduling changes, (b) FDA compounding bulks list updates, and (c) broader regulatory posture shifts. Accurate reporting on specific peptides requires distinguishing among these three distinct regulatory dimensions, each of which operates under separate legal frameworks.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.